A Phase 2 Evaluation Of Trc105 In Combination With Bevacizumab For The Treatment Of Recurrent Or Progresisve Gliblastoma That Has Progressed On Bevaci
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Type of Study: Drug
This study will determine if tumors shrink or if patients survive longer with TRC105 monoclonal antibody treatment in combination with bevacizumab, after his/her tumor has already grown while receiving bevacizumab treatment. The study will also evaluate how well patients tolerate the combination of
Criteria:
Eligible Patients Must Have Glioblastoma That Has Come Back Or Progressed While On Anti-Angiogenic T
Keywords:
105Gm-201, Brain Cancer, Brain Tumor, Gbm, Neuro-Oncology
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu